Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SLS-005 (trehalose), a low molecular weight disaccharide that stabilizes misfolded proteins and activates autophagy. It is being evaluated for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Trehalose API
Therapeutic Area: Neurology Product Name: SLS-005
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Seelos intends to use the net proceeds for the advancement of the development of its product candidates, including SLS-002 (ketamine hydrochloride) for the treatment of major depressive disorder at imminent risk of suicide.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $5.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 01, 2023
Details:
Seelos intends to use the net proceeds for the advancement of the development of its product candidates, including SLS-002 (ketamine hydrochloride) for the treatment of major depressive disorder at imminent risk of suicide.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $5.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 28, 2023
Details:
SLS-002 is intranasal racemic ketamine with two investigational new drug applications for the treatment of Acute Suicidal Ideation and Behavior in Major Depressive Disorder and in Post-Traumatic Stress Disorder.
Lead Product(s): Racemic Ketamine
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Seelos intends to use the net proceeds to advance the development of its product candidates, including SLS-002 (ketamine hydrochloride), for Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD).
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 21, 2023
Details:
SLS-002 is intranasal racemic ketamine with two investigational new drug applications for the treatment of Acute Suicidal Ideation and Behavior in Major Depressive Disorder and in Post-Traumatic Stress Disorder.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
SLS-005 is a low molecular weight disaccharide (0.342 kDa) that crosses the blood brain barrier and is thought to stabilize proteins and activate autophagy through the activation of Transcription Factor EB (TFEB), a key factor in lysosomal and autophagy gene expression.
Lead Product(s): SLS-005
Therapeutic Area: Neurology Product Name: SLS-005
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
SLS-002 is intranasal racemic ketamine hydrochloride with two investigational new drug applications for the treatment of Acute Suicidal Ideation and Behavior in Major Depressive Disorder and in Post-Traumatic Stress Disorder.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $11.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 10, 2023
Details:
SLS-004 is an investigational novel epigenome-editing approach to modulate expression of alpha-synuclein (α-synuclein) protein produced by SNCA gene.
Lead Product(s): SLS-004
Therapeutic Area: Neurology Product Name: SLS-004
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2023
Details:
SLS-002 is intranasal racemic ketamine hydrochloride (glutamate receptor antagonist) with two investigational new drug applications for the treatment of acute suicidal ideation and behavior in major depressive disorder and in post-traumatic stress disorder.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: SLS-002
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023